What records are connected here?
- Evidence lanes
- 2
- Source years
- 5
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials3,4,5Evidence: Large human trialsGut and digestion
Also called Larazotide acetate3
Larazotide is a synthetic eight-amino-acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly), recorded in FDA’s substance registry and also known as AT-1001 in its acetate form.3 It was developed for celiac disease. In a randomized, placebo-controlled trial of 342 adults with ongoing symptoms despite a gluten-free diet, the lowest of three strengths tested reduced symptoms more than placebo; the two higher strengths did not.4 No FDA approval is reported in the sources reviewed here. Larazotide does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.3,5,7
| What it is | A synthetic octapeptide, glycylglycyl-valyl-leucyl-valyl-glutaminyl-prolyl-glycine, according to FDA’s substance registry.3 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list larazotide.3,5 |
| Human evidence | Randomized, placebo-controlled trials in celiac disease, including one of 342 adults published in 2015, with mixed results.4 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Larazotide is a synthetic peptide of eight amino acids. FDA’s substance registry records it as larazotide and, as the acetate salt, as larazotide acetate and AT-1001.3
The 2015 trial authors describe it as a novel agent targeting the regulation of tight junctions, the seals between cells lining the gut.4
In a multicenter, randomized, double-blind trial published in 2015, 342 adults with celiac disease who still had symptoms after at least a year on a gluten-free diet received one of three strengths of larazotide or placebo for 12 weeks.4
The lowest strength met the main goal of fewer gastrointestinal symptoms than placebo, while the two higher strengths were no different from placebo on any outcome. Safety was comparable with placebo, and the authors described the results as mixed.4
ClinicalTrials.gov lists the 2015 trial (NCT01396213) as completed, and a Phase 2 trial in long COVID (NCT05747534) as completed in its August 18, 2026 record, which does not report findings.1,2
Evidence-strength label: Large randomized human trials. How this label is assigned
None of the sources reviewed here reports an approval of larazotide by FDA.3,5
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list larazotide.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Larazotide is not among them.6,7
Why only the lowest strength helped in the 2015 trial, and whether that benefit would hold in larger trials.4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Larazotide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Larazotide are a bounded selection, not every registration or paper about Larazotide. For the years before Larazotide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Larazotide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Larazotide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
Not FDA-approved; studied in clinical trials. In a randomized trial of 342 adults, only the lowest strength reduced celiac symptoms more than placebo. Larazotide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
Not FDA-approved; studied in clinical trials. In a randomized trial of 342 adults, only the lowest strength reduced celiac symptoms more than placebo. Larazotide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date August 18, 2026
ClinicalTrials.gov record NCT05747534↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05747534↗Source date August 18, 2026Literature metadata · added November 16, 2026
Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.↗Source date August 12, 2026Literature metadata · added November 16, 2026
Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.↗Source date March 17, 2022PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
8 of 8 selected trial records include at least one phase value; 8 of 8 include a status value in the retained structured contract.
5 of 5 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.
5 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span September 11, 2017 to August 18, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide.↗
Literature metadata
PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Gastroenterology · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026